Progressive Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Progressive Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie
Cenrifki (tolebrutinib) has been authorised by the EMA for therapeutic use in multiple sclerosis, including chronic progressive forms.
-
CLINICAL_TRIALS trial_result · 2026-08-11Clinical Trial Results: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis [Phase 3]
Phase III non-inferiority trial comparing subcutaneous versus intravenous ocrelizumab in relapsing and primary progressive multiple sclerosi…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Update: A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial evaluating ocrelizumab in participants with Progressive Multiple Sclerosis is active but not recruiting.
-
EMA approval · 2026-06-25EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie
Cenrifki (tolebrutinib) has been authorised in the EU for multiple sclerosis, including chronic progressive forms.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis [Phase 3]
A Phase 3 trial evaluating remibrutinib for efficacy and safety in secondary progressive multiple sclerosis is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis [Phase 4]
This Phase 4 clinical trial is evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of ocrelizumab in participants with R…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS [Phase 2]
Phase 2 trial evaluating monthly long-acting GA Depot injections (25 mg or 40 mg) for primary progressive multiple sclerosis has been termin…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: The Effects of a 12-week In-phase Bilateral Exercise Programme on the Corticospinal Plasticity in People With Progressive Multiple Sclerosis [NA]
This clinical trial update notes the completion of a 12-week in-phase bilateral exercise program evaluating its effect on corticospinal plas…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
This clinical trial update from Ondokuz Mayıs University investigates serum biomarkers GFAP, NfL, and VEGF and their relation to clinical pr…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis [Phase 1, Phase 2]
A Phase 1/2 clinical trial is assessing the safety and efficacy of Extracorporeal Photopheresis for Multiple Sclerosis, including Relapsing-…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Functional Outcomes From Diets in Multiple Sclerosis [NA]
This clinical trial update reports on functional outcomes from dietary interventions in people with relapsing-remitting multiple sclerosis a…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) [Phase 3]
A Phase 3 study to evaluate the efficacy, safety, and pharmacokinetics of a higher dose of ocrelizumab in adults with primary progressive mu…
-
CLINICAL_TRIALS withdrawal · 2026-03-30Clinical Trial Update: Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) [Phase 3]
Phase 3 clinical trial evaluating withdrawal of disease-modifying therapies in inactive secondary progressive multiple sclerosis patients ov…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis [Phase 3]
A Phase 3 trial compares fenebrutinib to ocrelizumab in adults with primary progressive multiple sclerosis; the study status is ACTIVE_NOT_R…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Obe-cel in Refractory Progressive Forms of Multiple Sclerosis [Phase 1]
A Phase 1 clinical trial update indicates Obecel (Obe-cel) for refractory progressive multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis [Phase 3]
Phase 3 clinical trial investigating Orelabrutinib for secondary progressive multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Intermittent Hypoxia in Persons With Multiple Sclerosis [NA]
A clinical trial update indicates a study evaluating intermittent hypoxia in people with Multiple Sclerosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Motor Asymmetry in Progressive Multiple Sclerosis Patients
A completed clinical trial update investigating motor asymmetry in patients with progressive multiple sclerosis.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis [Phase 1, Phase 2]
A Phase 1/2 clinical trial sponsored by Tr1X, Inc. is currently recruiting to evaluate a treatment for Primary Progressive Multiple Sclerosi…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis [Phase 2]
Phase 2 clinical trial assessing rituximab for cognitive and hand function in secondary progressive multiple sclerosis. The study is current…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating autologous mesenchymal stem cells as a regenerative treatment for multiple sclerosis, currently active…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis [Phase 2]
Phase 2 study evaluating N-acetylcysteine for neuroprotection in progressive multiple sclerosis; currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
This clinical trial update reports completion of a study evaluating the effect of ocrelizumab on choroid plexus changes in patients with pri…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis [Phase 1]
A Phase 1 clinical trial sponsored by Stanford University is evaluating anti-CD19 CAR-T cell therapy for non-relapsing and progressive forms…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis [Phase 3]
Phase 3 trial evaluating ocrelizumab in adults with primary progressive multiple sclerosis has posted results assessing efficacy and safety;…